2025
Imetelstat in myeloid malignancies: current data and future directions
Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, 25: 517-528. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.Peer-Reviewed Original ResearchMyelodysplastic syndromeLR-MDSClinical trialsPotential disease-modifying propertiesLow-risk myelodysplastic syndromesElevated liver enzymesLR-MDS patientsTreat myelodysplastic syndromeSearch of PubMedTransfusion independenceEssential thrombocythemiaInfusion reactionsMyeloid malignanciesDisease-modifying propertiesCombination therapySurvival benefitEffective telomerase inhibitorImetelstatTelomerase reactivationPatient populationLiver enzymesMyelofibrosisCancer cellsMalignancyConference abstracts
2024
Effects of prazosin treatment on liver enzymes are moderated by alcohol withdrawal symptoms in individuals with alcohol use disorder
Martins B, Fogelman N, Tate M, Hermes G, Sinha R. Effects of prazosin treatment on liver enzymes are moderated by alcohol withdrawal symptoms in individuals with alcohol use disorder. Alcohol Clinical And Experimental Research 2024, 48: 507-515. PMID: 38258493, PMCID: PMC10939766, DOI: 10.1111/acer.15263.Peer-Reviewed Original ResearchAlcohol withdrawal symptomsAlcohol use disorderEffect of prazosin treatmentWithdrawal symptomsPrazosin treatmentLiver enzyme levelsLiver enzymesAlanine transaminasePrazosin groupAlcohol drinking outcomesAspartate transaminaseGamma-glutamyltransferaseSeverity of AWSLiver enzymes alanine transaminaseWithdrawal severityDrinking outcomesElevated liver enzymesAUD treatmentTreatment effectsAmount of alcoholSignificant liver pathologyGamma-glutamyltransferase levelsEnzyme levelsRandomized Controlled TrialsDisordered background
2023
Sodium intake and the development of hypertensive disorders of pregnancy
Bank T, Grasch J, Chung J, Mercer B, McNeil R, Parry S, Saade G, Shanks A, Silver R, Simhan H, Yee L, Reddy U, Grobman W, Frey H. Sodium intake and the development of hypertensive disorders of pregnancy. American Journal Of Obstetrics & Gynecology MFM 2023, 5: 101166. PMID: 37741626, DOI: 10.1016/j.ajogmf.2023.101166.Peer-Reviewed Original ResearchConceptsHypertensive disordersHigh sodium intakeSodium intakeChronic hypertensionNonpregnant populationLow platelet count syndromeNeonatal intensive care unitNulliparous Pregnancy Outcomes StudyElevated liver enzymesGestational age neonatesFood frequency questionnaireLow sodium intakeIncidence risk ratioIntensive care unitWeeks of gestationPregnancy Outcomes StudyLack of associationChi-square testGestational hypertensionNeonatal outcomesNonpregnant stateSodium restrictionFrequency questionnairePreterm birthSingleton pregnanciesBaseline rotational thromboelastometry (ROTEM) values in a healthy, diverse obstetric population and parameter changes by pregnancy-induced comorbidities
Fiol A, Yoo J, Yanez D, Fardelmann K, Salimi N, Alian M, Mancini P, Alian A. Baseline rotational thromboelastometry (ROTEM) values in a healthy, diverse obstetric population and parameter changes by pregnancy-induced comorbidities. Baylor University Medical Center Proceedings 2023, 36: 562-571. PMID: 37614857, PMCID: PMC10443986, DOI: 10.1080/08998280.2023.2217534.Peer-Reviewed Original ResearchRotational thromboelastometryCoagulability statusObstetric populationROTEM valuesFIBTEM A10Elevated liver enzymesLow platelets (HELLP) syndromeMaximum clot firmnessClot formation timeBody mass indexPostpartum hemorrhage managementEXTEM A10Recent bleedingCesarean deliveryClot firmnessHypercoagulable profileGestational ageLiver diseasePostpartum hemorrhageRetrospective reviewMass indexBlack raceMaternal ageBlood productsHealthy criteria
2020
Acute Brain Injury in Infant Venoarterial Extracorporeal Membrane Oxygenation: An Autopsy Study.
Caturegli G, Cho S, White B, Chen L. Acute Brain Injury in Infant Venoarterial Extracorporeal Membrane Oxygenation: An Autopsy Study. Pediatric Critical Care Medicine 2020, 22: 297-302. PMID: 33055528, DOI: 10.1097/pcc.0000000000002573.Peer-Reviewed Original ResearchConceptsExtracorporeal membrane oxygenationVenoarterial extracorporeal membrane oxygenationAcute brain injuryHypoxic-ischemic brain injuryMembrane oxygenationMedian ageIntracranial hemorrhageExtracorporeal membrane oxygenation support durationExtracorporeal membrane oxygenation durationExtracorporeal membrane oxygenation initiationExtracorporeal membrane oxygenation patientsBrain injuryElevated liver enzymesAssociated with acute brain injuryApgar scoreGestational ageOxygenation durationTiming of acute brain injuryHepatic impairmentAnticoagulant therapyPathology recordsBirth weightOxygenation patientsOxygenation initiationAutopsied patientsManagement of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).
Okines A, Paplomata E, Wahl T, Wright G, Sutherland S, Jakobsen E, Valdes F, Chan A, Clark A, Conlin A, Lustberg M, Specht J, Pluard T, Zhu X, Krop I, Gelmon K, Slamon D, Ramos J, An G, Hamilton E. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). Journal Of Clinical Oncology 2020, 38: 1043-1043. DOI: 10.1200/jco.2020.38.15_suppl.1043.Peer-Reviewed Original ResearchAdverse eventsMedian timeControl armBreast cancerExposure-adjusted incidence ratesElevated liver enzymesMetastatic breast cancerCases of diarrheaMedian durationDose modificationTx groupIncidence rateLiver enzymesHigh incidenceDiarrheaTucatinibFirst onsetCapecitabineTrastuzumabHER2Significant inhibitionBilirubinLonger durationCycle 1PatientsThe Application of ROTEM in a Parturient With Antiphospholipid Syndrome in the Setting of Anticoagulation for Cesarean Delivery: A Case Report.
Fiol AG, Fardelmann KL, McGuire PJ, Merriam AA, Miller A, Alian A. The Application of ROTEM in a Parturient With Antiphospholipid Syndrome in the Setting of Anticoagulation for Cesarean Delivery: A Case Report. A&A Practice 2020, 14: e01182. PMID: 32224689, DOI: 10.1213/xaa.0000000000001182.Peer-Reviewed Case Reports and Technical NotesConceptsAntiphospholipid syndromeHeparin neutralizationDiagnosis of hemolysisElevated liver enzymesSetting of anticoagulationFresh frozen plasmaPartial thromboplastin timeCesarean deliveryLow plateletsTransfusion managementCase reportFrozen plasmaLiver enzymesThromboplastin timeParturientsSyndromeIntrinsic pathwayAnticoagulationROTEMDiagnosisNeutralizationHeparin
2019
Early Preterm Preeclampsia Outcomes by Intended Mode of Delivery
Coviello E, Iqbal S, Grantz K, Huang C, Landy H, Reddy U. Early Preterm Preeclampsia Outcomes by Intended Mode of Delivery. Obstetric Anesthesia Digest 2019, 39: 187-188. DOI: 10.1097/01.aoa.0000603672.77426.4d.Peer-Reviewed Original ResearchSevere featuresEarly preterm deliveryEarly preterm preeclampsiaEarly preterm birthElevated liver enzymesSyndrome of hemolysisIntended modePreeclampsia outcomesNeonatal outcomesPregnant patientsPreterm deliveryPreterm preeclampsiaPreterm birthLow plateletsMaternal mortalityLiver enzymesPaucity of studiesPreeclampsiaOutcomesDeliveryEclampsiaMorbidityPatientsPregnancySyndromeAcute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang H, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal For ImmunoTherapy Of Cancer 2019, 7: 47. PMID: 30777137, PMCID: PMC6380028, DOI: 10.1186/s40425-019-0532-1.Peer-Reviewed Original ResearchConceptsImmune-related adverse reactionsGrade 3 colitisGastrointestinal reactionsLiver injuryClinical historyImmune checkpoint inhibitor-related colitisBackgroundImmune checkpoint inhibitorsElevated liver enzymesPD-1 inhibitorsTNF-α agentsAcute liver injuryInflammatory bowel diseaseOne-time infusionInfliximab therapyAcute hepatitisCheckpoint inhibitorsRescue therapyAdvanced malignanciesBiologic agentsBowel diseaseLiver profileCase presentationWePatient populationCTLA-4Final diagnosis
2018
Disseminated Intravascular Coagulation
Hossain N, Paidas M. Disseminated Intravascular Coagulation. 2018, 479-486. DOI: 10.1002/9781119129400.ch31.Peer-Reviewed Original ResearchDisseminated intravascular coagulationAmniotic fluid embolismIntravascular coagulationDiagnosis of DICLow platelet count syndromeObstetrical disseminated intravascular coagulationTissue factorMicrovesicular fatty infiltrationAcute fatty liverElevated liver enzymesMassive obstetric hemorrhageSignificant maternal mortalityObstetric causesObstetric hemorrhageSupportive careBlood lossCatastrophic complicationLiver failureMedical complicationsFatty liverFatty infiltrationMaternal hepatocytesMaternal mortalityLiver enzymesBlood productsDuvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1311-1317. PMID: 30033575, PMCID: PMC6220789, DOI: 10.1002/ajh.25228.Peer-Reviewed Original ResearchConceptsIndolent non-Hodgkin lymphomaDose-limiting toxicityNon-Hodgkin lymphomaClinical activityINHL patientsHematologic malignanciesClinical developmentGrade 3 transaminase elevationMedian progression-free survivalOral dual inhibitorAcute respiratory failureE. coli sepsisElevated liver enzymesOpen-label studyAcceptable safety profileAdvanced hematologic malignanciesDose-escalation phaseGrade 3 rashProgression-free survivalSevere adverse eventsPhase 1 studyDuration of responseFavorable clinical activityFurther clinical developmentBID cohort
2017
Care under the Influence
Fins J, Knowlton S. Care under the Influence. The Hastings Center Report 2017, 47: 8-9. PMID: 28074588, DOI: 10.1002/hast.675.Peer-Reviewed Original ResearchConceptsER physiciansWork-related callsImpaired physiciansAffiliated clinicsAlcohol consumptionER doctorsPhysiciansElevated liver enzymesEmergency roomMedical historyBlood alcohol levelsLab resultsDrinking of waterLiver enzymesHospitalistsAlcohol levelsDrinkingInternistsStairsDoctorsAlcoholAdmitting
2015
Follicular pancreatitis: a distinct form of chronic pancreatitis—an additional mimic of pancreatic neoplasms
Gupta R, Xie B, Patton K, Lisovsky M, Burks E, Behrman S, Klimstra D, Deshpande V. Follicular pancreatitis: a distinct form of chronic pancreatitis—an additional mimic of pancreatic neoplasms. Human Pathology 2015, 48: 154-162. PMID: 26563969, PMCID: PMC5023064, DOI: 10.1016/j.humpath.2015.09.017.Peer-Reviewed Original ResearchConceptsFollicular pancreatitisReactive germinal centersGerminal centersAutoimmune pancreatitisPancreatic neoplasmsLymphoid folliclesDilated main pancreatic ductVariant of chronic pancreatitisElevated liver enzymesGranulocytic epithelial lesionsIntraductal pancreatic mucinous neoplasmMain pancreatic ductPancreatic mucinous neoplasmsStoriform fibrosisObliterative phlebitisAbdominal painIncidental diagnosisEpithelial lesionsPancreatic massPancreatitis casesMucinous neoplasmsChronic pancreatitisLymphoid aggregatesHistological featuresPancreatic duct
2013
The curious case of a Klatskin tumor.
Njei B, Konjeti V, Sanchez H. The curious case of a Klatskin tumor. Connecticut Medicine 2013, 77: 591-4. PMID: 24369037.Peer-Reviewed Original ResearchConceptsKlatskin tumorHepatic ductAbsence of early symptomsAdjuvant treatment regimensAdvanced incurable stageHepato-biliary malignancyCurative treatment modalityElevated liver enzymesLeft hepatic ductLiver function markersStandard of careLeft hepatic ductsPerihilar tumorsAsymptomatic patientsIncurable stageSurvival outcomesTreatment regimensTreatment modalitiesElderly patientsKlatskinLiver enzymesTumorPatientsPatient diagnosisFunctional markers
2011
HIV, hepatitis B, and hepatitis C in Zambia
Kapembwa KC, Goldman JD, Lakhi S, Banda Y, Bowa K, Vermund SH, Mulenga J, Chama D, H BH. HIV, hepatitis B, and hepatitis C in Zambia. Journal Of Global Infectious Diseases 2011, 3: 269-274. PMID: 21887060, PMCID: PMC3162815, DOI: 10.4103/0974-777x.83534.Peer-Reviewed Original ResearchHepatitis B coinfectionAntiretroviral therapyHepatitis BElevated AST/ALTHepatitis B surface antigenActive hepatitis BART-eligible adultsViral hepatitis coinfectionElevated liver enzymesHepatitis C antibodyHepatitis C infectionAST/ALTTertiary care facilityB surface antigenHCV AbHepatitis coinfectionC infectionHepatitis CHepatitis screeningTertiary hospitalLiver enzymesEpidemiologic dataC antibodyLow prevalenceCare facilities
2010
Effects of Hypoxia-Inducible Factor-1α Overexpression in Pregnant Mice Possible Implications for Preeclampsia and Intrauterine Growth Restriction
Tal R, Shaish A, Barshack I, Polak-Charcon S, Afek A, Volkov A, Feldman B, Avivi C, Harats D. Effects of Hypoxia-Inducible Factor-1α Overexpression in Pregnant Mice Possible Implications for Preeclampsia and Intrauterine Growth Restriction. American Journal Of Pathology 2010, 177: 2950-2962. PMID: 20952590, PMCID: PMC2993274, DOI: 10.2353/ajpath.2010.090800.Peer-Reviewed Original ResearchConceptsIntrauterine growth restrictionHIF-1αControl micePregnant miceGrowth restrictionFetal intrauterine growth restrictionSoluble vascular endothelial growth factor receptor-1Vascular endothelial growth factor receptor 1Serum sFlt-1Elevated liver enzymesLiver enzyme levelsMicroangiopathic hemolytic anemiaPregnancy-specific disorderHypoxia-inducible factor-1αComplete blood countGestational day 8Growth factor receptor 1HIF-1α overexpressionFactor receptor 1Hypoxia-inducible factorPlacental weightPregnant controlsSoluble endoglinBlood pressureSignificant anemia
2009
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
LoRusso P, Markman B, Tabernero J, Shazer R, Nguyen L, Heath E, Patnaik A, Papadopoulos K. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2009, 27: 3502-3502. DOI: 10.1200/jco.2009.27.15_suppl.3502.Peer-Reviewed Original ResearchAdverse eventsPhase I dose-escalation studyI dose-escalation studyDurable stable diseaseElevated hepatic transaminasesFood-induced increaseElevated liver enzymesNausea/vomitingSerious adverse eventsAdvanced solid tumorsDose-escalation studyPI3K pathway inhibitionClass I PI3K isoformsTumor growth inhibitionPI3K pathwayPharmacodynamic modulationQD regimenStable diseaseBID regimenHepatic transaminasesNeurological complaintsRepeat dosingPI3K isoformsPlasma insulinTolerable doses
2007
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma
Duffy A, Kortmansky J, Schwartz G, Capanu M, Puleio S, Minsky B, Saltz L, O’Reilly E, Kelsen D. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Annals Of Oncology 2007, 19: 86-91. PMID: 17878176, DOI: 10.1093/annonc/mdm441.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDeoxycytidineDisease ProgressionErlotinib HydrochlorideFemaleGemcitabineHumansMaleMaximum Tolerated DoseMiddle AgedNeutropeniaPancreatic NeoplasmsProtein Kinase InhibitorsQuinazolinesRadiotherapy, AdjuvantSurvival AnalysisThrombocytopeniaTreatment OutcomeConceptsDose level 1Radiation therapyDaily erlotinibAdvanced pancreas cancerDose level 2Dose of erlotinibGemcitabine-based chemoradiationMTD of erlotinibAdvanced pancreatic cancerElevated liver enzymesPartial response rateDose-limiting toxicityPoor prognostic cancerDose delaysDose gemcitabineGemcitabine 1000Stable diseaseWeekly gemcitabineMedian survivalOverall survivalAdditional patientsPancreas cancerPancreatic cancerPancreatic adenocarcinomaLiver enzymes
2005
Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience.
Adamkiewicz T, Haight A, Mazur M, Baker K, Szabolcs P, Kedar A, Chiang K, Krishnamurti L, Wagner J, Wingard J, Yeager A. Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience. Blood 2005, 106: 2044. DOI: 10.1182/blood.v106.11.2044.2044.Peer-Reviewed Original ResearchUnrelated cord blood transplantationAnti-thymocyte globulinSickle cell diseaseHigh-risk sickle cell diseaseReduced-intensity regimensMycophenolate mofetilYo maleDonor engraftmentAutologous reconstitutionDonor originReduced-intensity preparative regimenUnrelated cord blood unitsAcute grade IIIConventional myeloablative regimensExtensive chronic GVHDGrade 1 mucositisGrade III mucositisGrade IV GVHDMyeloablative preparative regimensParainfluenza 3 infectionSevere acute GVHDSustained donor engraftmentTotal lymphoid irradiationTransfusion-induced alloimmunizationElevated liver enzymes
2004
Aberrant left hepatic artery in laparoscopic antireflux procedures
Klingler P, Seelig M, Floch N, Branton S, Freund M, Katada N, Hinder R. Aberrant left hepatic artery in laparoscopic antireflux procedures. Surgical Endoscopy 2004, 18: 807-811. PMID: 15054654, DOI: 10.1007/s00464-003-8280-0.Peer-Reviewed Original ResearchConceptsLaparoscopic antireflux surgeryHepatic arteryAntireflux surgeryTransiently elevated liver enzymesLiver enzymesMean blood lossLaparoscopic antireflux proceduresElevated liver enzymesAberrant left hepatic arteryImpaired liver functionFollow-up dataLeft hepatic arteryPostoperative morbidityBlood lossPostoperative symptomsDiagnostic workupAntireflux procedureHiatal dissectionClinical complaintsClinical dataFollow-upOperative reportsLiver functionAnatomical variationsPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply